Apr 13, 2021
Paul D. Slowey, Ph.D., is the Owner and CEO of Oasis Diagnostics® Corporation, a company founded in 2002 to address the need for non-invasive saliva-based technology. He is also the Co-founder of the North American Saliva Symposium and a member of both the Oregon Bioscience Association and Life Science Washington. With over 35 years of combined experience in diagnostics, pharmaceuticals, and organic chemistry, Paul is considered a pioneer in oral fluid diagnostics.
As an entrepreneur with several issued patents, Paul is experienced in marketing, business development, sales, licensing, strategic partnering, corporate management, device design, and international distribution. He has worked with start-up organizations, Fortune 500 companies, and everything in between. He is also a widely published and sought-after speaker on HIV diagnosis, liquid biopsy testing for cancer, nucleic acid testing, and more.
In this episode…
From mouth-watering to slobbering sputum, spit dominates the English language—but it’s probably the furthest thing from your mind when you think of style. Nevertheless, saliva is the new trendsetter making waves in the diagnostics industry. And, even though COVID-19 has put saliva in the spotlight, rapid testing isn’t the only reason demand is soaring.
Oral fluid diagnostics expert Paul D. Slowey will tell you that spit is the new “it” specimen for diagnosing all kinds of diseases. It’s easy to collect, non-invasive, and contains information about everything, from your ancestry to your current health status. Some saliva tests can even diagnose lung cancer in as little as 30 minutes. Plus, it’s safer and cheaper to obtain samples than the old-fashioned collection methods. And that’s just some of what spit is doing these days.
Join Carl J. Cox in this episode of the Measure Success Podcast as he sits down with Paul D. Slowey, Owner and CEO of Oasis Diagnostics® Corporation, to discuss why saliva is now in fashion—well, at least when it comes to diagnostics. Listen in as Paul explains why liquid biopsies are gaining recognition in disease detection, what’s changing in the world of telehealth, and how a contract with the National Institutes of Health (NIH) has caused his company’s growth to skyrocket. Stay tuned!